컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

Congress of the European Society of Clinical Microbiology and Infectious Diseases

11 April - 15 April, 2025, Austria

5-day antibiotic treatment viable in CAP patients with clinical stability

2025-06-30

Antibiotic treatment may be done for 5 days, as opposed to at least 7 days, in hospitalized patients with community-acquired pneumonia (CAP) who had achieved clinical stability by day 3 to 5, suggests a study presented at ESCMID Global 2025.
BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization

2025-06-30

BNT162b2 JN.1-adapted vaccine provides protection against COVID-19-related hospitalization in Europe, a case-control study using the id.DRIVE platform has shown.
Dual therapy as good as three-drug HIV regimen in patients coinfected with TB

2025-06-30

In the treatment of HIV in individuals who are receiving rifampin-based therapy for tuberculosis, a two-drug antiretroviral (ART) regimen comprising double-dose dolutegravir plus lamivudine compares favourably with a three-drug regimen of efavirenz, tenofovir, and lamivudine in terms of suppressing viral load, as shown in a study.
FMT bodes well for AMR

2025-06-30

The PROFIT trial turns waste into gains by showing how faecal microbiota transplantation (FMT) can combat antimicrobial resistance (AMR) in patients with liver cirrhosis.
Ibrexafungerp expands salvage antifungal treatment options as a pill

2025-06-30

For patients with fungal diseases that preclude receiving standard treatment or IV antifungals primarily due to refractoriness or resistance, ibrexafungerp can serve as an effective salvage treatment given orally, offering a positive risk-benefit ratio up to the final data cut-off in the FURI trial
RSV-ARI nearly triples mortality risk in new study

2025-06-30

Acute respiratory infection caused by respiratory syncytial virus (RSV-ARI) nearly triples the risk of death, particularly among individuals with chronic underlying respiratory conditions, as shown in a nationwide cohort study in Denmark.
Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

2025-06-30

A single dose of adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVPreF3 OA) is efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) over three RSV seasons in older adults aged ≥60 years, according to results of the phase III AReSVi-006 trial presented at ESCMID Global 2025.
Tapered vancomycin dosing reduces CDI recurrence

2025-06-30

Tapering the dose of vancomycin over 2 weeks following initial 14-day therapy appears to work better than the 14-day fixed dosing at reducing the recurrence of Clostridioides difficile infection (CDI), as shown in the TAPER-V trial.
Temocillin a good alternative to carbapenems in treatment of bacteraemia due to 3GCR-E

2025-06-30

The use of temocillin demonstrates comparable efficacy and safety to carbapenems for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (3GCR-E), primarily from urinary sources, reports a study.
TrUST study heralds new era for TB diagnosis

2025-06-30

A suite of deep learning (DL) models to automate tuberculosis (TB) risk assessment from lung ultrasound (LUS) images fulfils the WHO criteria for a sputum-free TB triage test and outwits human experts in the TrUST study.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브